Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma

Keyphrases

• Mucosal Melanoma 100%
• Ipilimumab 80%
• Pembrolizumab 60%
• No Significant Difference 40%
• Objective Response Rate 40%
• Complete Response 40%
• 95% Confidence Interval 40%
• Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) 40%
• Anti-PD-1 Immunotherapy 40%
• Standard of Care 20%
• Primary Tumor 20%
• Progression-free Survival 20%
• Distant Metastasis 20%
• Single Center 20%
• Mucosal Surfaces 20%
• Cohort Analysis 20%
• Published Data 20%
• Risk-benefit Ratio 20%
• Non-surgical 20%
• Primary Tumor Location 20%
• Metastatic Melanoma 20%
• Locally Advanced 20%
• Anti-PD-1 Therapy 20%
• Therapeutic Guidelines 20%
• Vulvovaginal 20%
• Head-and-neck 20%
• Median Progression-free Survival 20%
• Cutaneous Melanoma 20%
• Immune Checkpoint Inhibitors 20%
• First-line Immunotherapy 20%

Medicine and Dentistry

• Immunotherapy 100%
• Mucosal Melanoma 100%
• Ipilimumab 80%
• Pembrolizumab 60%
• Primary Tumor 40%
• Progression Free Survival 40%
• Melanoma Skin Cancer 40%
• Cohort Analysis 20%
• Survival Rate 20%
• Distant Metastasis 20%
• Mucosal Surface 20%
• Neck 20%
• Risk-Benefit Ratio 20%
• Immune Checkpoint Inhibitor 20%
• Diseases 20%
• Median Follow Up 20%